Skip to main content


Embolus permanent protector stent-filter Worldwide, stroke is the number three cause of death and the number one cause of adult disability. More women die of stroke than breast cancer. Today, there is no viable treatment for stroke. There are two kinds of strokes, ischemic which involves a clot (85% of...
Read More


Fast and Reliable ultra-sensitive Identification of Streptococcus B at deliverY Sepsis, pneumonia and sometimes meningitis caused by Group B Streptococcus (GBS) are the most common severe bacterial diseases in infants. They account for high morbidity and mortality rates; despite the extent of implemented prevention strategies, GBS is still the leading...
Read More


3D Printed Biomaterials and OPTimized for Regeneration Oral Bone Bone regeneration is frequently used in dentistry especially in implantology. The use of biomaterials for bone regeneration or alveolar bone preservation is a reliable treatment option compared to autologous bone involving higher morbidity. However, the commercially available biomaterials for dental bone...
Read More


Treatment of breast cancer with epigenetic specific tools The partners of the TREATBEST consortium are joining forces in order to leverage disruptive science in the field of personalized breast cancer treatment. The final product will be a CE-marked IVD test predicting the treatment benefit for patients with triple-negative breast cancer,...
Read More


Optimization of the treatment with HepaMune in fibro-inflammatory chronic liver diseases The aim of the IMPROVE project is to develop a new cell therapy product that will be used for the treatment of fibro-inflammatory chronic liver diseases. The objective is to develop a product exhibiting increased immuno-modulatory and anti-inflammatory potential,...
Read More


The treatment of patients in clinical practice relies on the results of randomized clinical trials. The statistical methods currently used to test the treatment effects in such trials take into account a single criterion called "primary endpoint". This is an incomplete assessment of trial results, especially in oncology and chronic...
Read More

Secure your place for BioWin Day: empowering health, the premier event for professionals and decision-makers in the life sciences industry.

Register here!